Photo by aaronburden from unsplash
Between 2014 and 2019, the SToP‐C trial observed a halving in HCV incidence in four Australian prisons following scale‐up of direct‐acting antiviral (DAA) therapy. However, the contribution of HCV treatment… Click to show full abstract
Between 2014 and 2019, the SToP‐C trial observed a halving in HCV incidence in four Australian prisons following scale‐up of direct‐acting antiviral (DAA) therapy. However, the contribution of HCV treatment to this decline is unclear because the study did not have a control group. We used modeling to consider this question.
Keywords:
treatment;
study;
evaluating prevention;
prevention;
hcv treatment
Journal Title: Hepatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!